Speaker(s): 

William Leach, MD, Fellow, and Justin Coles, MD, Fellow, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Evaluate non inferiority trial regarding complicated UTI, including acute pyelonephritis between IV cefepime-taniborbactam or meropenem

2. Review the prespecified superiority analysis of the primary outcome after confirmation of noninferiority

3. Identify the pervasive nature of recurrent UTIs in the female population and the lack of effective prophylaxis/treatments

4. Discuss the effectiveness of probiotics to decrease recurrent UTIs in females

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stanley Martin, MD; Julie Gombert, RN; Bradley Lauver, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.